ATE vs. RVX, AEZS, APS, MBX, BCT, HBP, and WLLW
Should you be buying Antibe Therapeutics stock or one of its competitors? The main competitors of Antibe Therapeutics include Resverlogix (RVX), Aeterna Zentaris (AEZS), Aptose Biosciences (APS), Microbix Biosystems (MBX), BriaCell Therapeutics (BCT), Helix BioPharma (HBP), and Willow Biosciences (WLLW). These companies are all part of the "medical" sector.
Antibe Therapeutics (TSE:ATE) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
Resverlogix has lower revenue, but higher earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Resverlogix had 1 more articles in the media than Antibe Therapeutics. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Antibe Therapeutics. Resverlogix's average media sentiment score of 1.78 beat Antibe Therapeutics' score of 0.00 indicating that Resverlogix is being referred to more favorably in the news media.
Resverlogix received 121 more outperform votes than Antibe Therapeutics when rated by MarketBeat users. Likewise, 84.01% of users gave Resverlogix an outperform vote while only 74.41% of users gave Antibe Therapeutics an outperform vote.
Antibe Therapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Resverlogix has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Resverlogix's return on equity of 0.00% beat Antibe Therapeutics' return on equity.
Summary
Resverlogix beats Antibe Therapeutics on 9 of the 11 factors compared between the two stocks.
Get Antibe Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Antibe Therapeutics Competitors List
Related Companies and Tools
